Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
James Brooker
OpenAlex ID:
A5113071784
Risankizumab for Ulcerative Colitis
2024
·
Edouard Louis
, Stefan Schreiber
, et al.
·
JAMA
·
134
PDF
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2023
·
Silvio Danese
, Remo Panaccione
, et al.
·
The Lancet. Gastroenterology & hepatology
·
74
PDF
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial
2026
·
Anita Afzali
, Silvio Danese
, et al.
·
Inflammatory Bowel Diseases
·
3
Show more works
View as search
Works count:
3
Citation count:
208
H-index:
3
I10-index:
2
Year
Topic
Type
